BioRestorative Therapies Reports 2024 Financials
Ticker: BRTX · Form: 8-K · Filed: Mar 27, 2025 · CIK: 1505497
Sentiment: neutral
Topics: financial-results, conference-call
Related Tickers: BRTX
TL;DR
BRTX dropped 2024 earnings report, conference call scheduled for March 27.
AI Summary
BioRestorative Therapies, Inc. filed an 8-K on March 27, 2025, reporting financial results for the year ended December 31, 2024, and announcing a conference call. The filing also includes information on the company's operations and financial condition, as well as Regulation FD disclosures.
Why It Matters
This filing provides investors with the company's year-end financial performance and outlook, crucial for assessing its current health and future prospects.
Risk Assessment
Risk Level: medium — The filing contains financial results which can be volatile and impact stock price.
Key Players & Entities
- BioRestorative Therapies, Inc. (company) — Registrant
- March 27, 2025 (date) — Date of Report
- December 31, 2024 (date) — Fiscal Year End
- 40 Marcus Drive Melville, New York 11747 (address) — Principal Executive Offices
- (631) 760-8100 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose is to report the financial results for the year ended December 31, 2024, and to announce a conference call.
When was this 8-K filed?
This 8-K was filed on March 27, 2025.
What is the fiscal year-end for BioRestorative Therapies, Inc.?
The fiscal year-end for BioRestorative Therapies, Inc. is December 31.
What is the principal executive office address for the company?
The principal executive office is located at 40 Marcus Drive, Melville, New York 11747.
What other information is included in this filing besides financial results?
The filing also includes information on the company's operations and financial condition, and Regulation FD disclosures.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 27, 2025 regarding BioRestorative Therapies, Inc. (BRTX).